All Articles

BetterAge's new executive team signals a potent strategy: combining deep industry partnerships with advanced AI to scale in the competitive elder care market.

As autonomous AI agents begin to dominate internet traffic, a new cybersecurity battleground is emerging. We explore the shift to agent trust management.

Whimstay's new feature lets you book a vacation home hours before check-in, challenging hotels and solving the industry's spontaneity problem.

At VivaTech 2026, JCDecaux unveiled a bus shelter that fights heatwaves and AI-driven ads, blurring the line between public service and modern commerce.

A silent productivity drain is costing businesses dearly. Over half the workforce aged 40-60 is managing elder care, and the financial and career toll is immense.

A lost Kazakh oil license reveals more than a regulatory slip-up; it exposes a bitter shareholder war and the high cost of corporate negligence.

After 75 years, the Velan family has sold its controlling stake in the iconic valve maker. A deep dive into the C$204M deal and what it means for the future.

Tri Delta’s 27-year, $185M partnership with St. Jude is more than charity. It's a masterclass in grassroots economic power fueling life-saving innovation.

A new wave of advanced cancer drugs is set to upend the market. As the EGFR inhibitor space surges towards $16B, we analyze the strategies behind the disruption.

As AI's hunger for processing power outstrips supply, a new class of specialized cloud providers is emerging to challenge the giants. But can they deliver?

Fulton Bank's latest CSR report details hundreds of millions in community investment. Is this just philanthropy, or a calculated strategy for lasting resilience?

Beyond the balance sheet, a major Icelandic bank's latest bond issuance reveals a sophisticated strategy for navigating global markets and regulatory demands.

Beyond the perfect steak, a new model for business success emerges, blending operational mastery with the strategic art of 'edvertising.' A deep dive.

As biopharma navigates a maze of privacy laws and AI, a new platform aims to centralize patient consent, turning a compliance nightmare into a bridge for trust.

Calgary's Douglas Vermeeren faces new fraud charges despite a 10-year ban. His case reveals a high-stakes battle between regulators and persistent predators.

As AI drug discovery faces a crucial test, Terray Therapeutics hires a proven dealmaker. Can Lisa Decker translate digital promise into clinical reality?

With the appointment of 'serial scaler' Jose Costa, RealManage and its PE backer signal an aggressive new era for the HOA management industry.

As Netflix preps its Q2 2026 report, investors look past subscriber numbers to the real story: the success of its ad-supported tiers and gaming bets.

Immuta's expanded Databricks partnership introduces a new security paradigm for autonomous AI, promising to turn a critical risk into a commercial advantage.

As AI promises to revolutionize medicine, enterprises face complex challenges. A new ISG study aims to chart the critical partner ecosystem.